Expand all sections

Tirzepatide

Mounjaro

Extended indication Extension of indication to include chronic weight management, including weight loss and weight mai
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Tirzepatide
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension
Main indication Other metabolism and Endocrinology
Extended indication Extension of indication to include chronic weight management, including weight loss and weight maintenance, for MOUNJARO.
Proprietary name Mounjaro
Manufacturer Eli Lilly
Portfolio holder Eli Lilly
Mechanism of action Other, see general comments
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)
Additional remarks Gecombineerde GIP/GLP-1 agonist. Tirzepatide is één enkel molecuul.

Registration

Registration route Centralised (EMA)
ATMP No
Submission date March 2023
Expected Registration January 2024
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

References https://www.farmacotherapeutischkompas.nl
Additional remarks De kosten voor een 0,5 ml injectievloeistof bevattende Tirzepatide 10 mg/ml bedragen € 102,05.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.